Literature DB >> 26053010

Diagnostic performances of clinical laboratory tests using Triton X-100 to reduce the biohazard associated with routine testing of Ebola virus-infected patients.

Massimo Tempestilli, Luigia Pucci, Stefania Notari, Antonino Di Caro, Concetta Castilletti, Maria Rosaria Rivelli, Chiara Agrati, Leopoldo Paolo Pucillo.   

Abstract

BACKGROUND: Ebola virus, an enveloped virus, is the cause of the largest and most complex Ebola virus disease (EVD) outbreak in West Africa. Blood or body fluids of an infected person may represent a biohazard to laboratory workers. Laboratory tests of virus containing specimens should be conducted in referral centres at biosafety level 4, but based on the severity of clinical symptoms, basic laboratories might be required to execute urgent tests for patients suspected of EVD. The aim of this work was to compare the analytical performances of laboratory tests when Triton X-100, a chemical agent able to inactivate other enveloped viruses, was added to specimens.
METHODS: Results of clinical chemistry, coagulation and haematology parameters on samples before and after the addition of 0.1% (final concentration) of Triton X-100 and 1 h of incubation at room temperature were compared.
RESULTS: Overall, results showed very good agreement by all statistical analyses. Triton X-100 at 0.1% did not significantly affect the results for the majority of the analytes tested.
CONCLUSIONS: Triton X-100 at 0.1% can be used to reduce the biohazard in performing laboratory tests on samples from patients with EVD without affecting clinical decisions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26053010     DOI: 10.1515/cclm-2015-0119

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

1.  Inactivating Zaire Ebolavirus in Whole-Blood Thin Smears Used for Malaria Diagnosis.

Authors:  Todd A. Cutts; Bradley W. M. Cook; Guillaume Poliquin; James E. Strong; Steven S Theriault
Journal:  J Clin Microbiol       Date:  2016-02-10       Impact factor: 5.948

2.  Ebola Virus Inactivation by Detergents Is Annulled in Serum.

Authors:  Jeroen J A van Kampen; Andrei Tintu; Henk Russcher; Pieter L A Fraaij; Chantal B E M Reusken; Mikel Rijken; Jaap J van Hellemond; Perry J J van Genderen; Rob Koelewijn; Menno D de Jong; Elaine Haddock; Robert J Fischer; Vincent J Munster; Marion P G Koopmans
Journal:  J Infect Dis       Date:  2017-10-17       Impact factor: 5.226

Review 3.  Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks.

Authors:  Barbara Bartolini; Cesare Em Gruber; Marion Koopmans; Tatjana Avšič; Sylvia Bino; Iva Christova; Roland Grunow; Roger Hewson; Gulay Korukluoglu; Cinthia Menel Lemos; Ali Mirazimi; Anna Papa; Maria Paz Sanchez-Seco; Aisha V Sauer; Hervè Zeller; Carla Nisii; Maria Rosaria Capobianchi; Giuseppe Ippolito; Chantal B Reusken; Antonino Di Caro
Journal:  Euro Surveill       Date:  2019-01

4.  Effective chemical virus inactivation of patient serum compatible with accurate serodiagnosis of infections.

Authors:  M M Remy; M Alfter; M-N Chiem; M T Barbani; O B Engler; F Suter-Riniker
Journal:  Clin Microbiol Infect       Date:  2018-10-28       Impact factor: 8.067

5.  Status, quality and specific needs of Ebola virus diagnostic capacity and capability in laboratories of the two European preparedness laboratory networks EMERGE and EVD-LabNet.

Authors:  Chantal B Reusken; Ramona Mögling; Pieter W Smit; Roland Grunow; Giuseppe Ippolito; Antonino Di Caro; Marion Koopmans
Journal:  Euro Surveill       Date:  2018-05

6.  Analysis of Inactivation of SARS-CoV-2 by Specimen Transport Media, Nucleic Acid Extraction Reagents, Detergents, and Fixatives.

Authors:  Stephen R Welch; Katherine A Davies; Hubert Buczkowski; Nipunadi Hettiarachchi; Nicole Green; Ulrike Arnold; Matthew Jones; Matthew J Hannah; Reah Evans; Christopher Burton; Jane E Burton; Malcolm Guiver; Patricia A Cane; Neil Woodford; Christine B Bruce; Allen D G Roberts; Marian J Killip
Journal:  J Clin Microbiol       Date:  2020-10-21       Impact factor: 5.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.